A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled Dose-Range Finding Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
MK0431, also known as sitagliptin phosphate, is positioned within the competitive landscape of Type 2 diabetes treatments, particularly among DPP-4 inhibitors. The study's completion indicates that Merck Sharp & Dohme LLC has advanced its understanding of MK0431's efficacy and safety profile. Given the increasing prevalence of Type 2 diabetes globally, successful outcomes could enhance market share against existing therapies, including other DPP-4 inhibitors and GLP-1 receptor agonists. The results may also support further development and potential combination therapies, aligning with current trends in diabetes management. Diligence should focus on market access strategies and potential pricing models in light of competitive pressures.
Indication: Diabetes Mellitus, Type II
Modality: small molecule
Target: Dipeptidyl peptidase-4 (DPP-4) inhibition
Sponsor: Merck Sharp & Dohme LLC
Source URL: ClinicalTrials.gov
Source updated: Mar 28, 2017
Ingested: Jun 16, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Dipeptidyl peptidase-4 (DPP-4) inhibition
View original source fields
Condition raw: Diabetes Mellitus, Type II
Condition normalized: Diabetes Mellitus, Type II
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Dipeptidyl peptidase-4 (DPP-4) inhibition
Target normalized: Dipeptidyl peptidase-4 (DPP-4) inhibition